Humacyte (NASDAQ:HUMA - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Friday.
A number of other equities analysts also recently commented on the stock. HC Wainwright assumed coverage on shares of Humacyte in a research note on Wednesday, May 14th. They set a "buy" rating and a $4.00 target price on the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of Humacyte in a research report on Wednesday, July 9th. Finally, Benchmark cut their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.71.
View Our Latest Stock Report on HUMA
Humacyte Stock Performance
Shares of HUMA stock traded down $0.09 during trading hours on Friday, hitting $2.33. The company's stock had a trading volume of 1,554,268 shares, compared to its average volume of 3,783,122. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.79. The company has a 50 day moving average of $2.35 and a 200 day moving average of $2.79. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36.
Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. Equities analysts expect that Humacyte will post -1.27 earnings per share for the current year.
Institutional Trading of Humacyte
Large investors have recently made changes to their positions in the stock. Heights Capital Management Inc. acquired a new stake in Humacyte in the 1st quarter worth about $6,863,000. RA Capital Management L.P. acquired a new stake in shares of Humacyte in the first quarter worth approximately $5,648,000. Woodline Partners LP boosted its position in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company's stock worth $14,386,000 after acquiring an additional 2,000,268 shares during the last quarter. Monashee Investment Management LLC acquired a new position in Humacyte during the first quarter worth approximately $3,410,000. Finally, CenterBook Partners LP purchased a new position in Humacyte during the fourth quarter worth approximately $6,463,000. Institutional investors and hedge funds own 44.71% of the company's stock.
About Humacyte
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Further Reading
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
